What is the role of kinase inhibitors in the treatment of hepatic hemangiomas?

Updated: Jun 17, 2019
  • Author: David C Wolf, MD, FACP, FACG, AGAF, FAASLD; Chief Editor: BS Anand, MD  more...
  • Print
Answer

Until relatively recently, no medical therapy capable of reducing the size of hepatic hemangiomas had been described. A case report in 2008 demonstrated reduction in the size of hepatic hemangiomas in a patient treated for colon cancer. The patient had received bevacizumab, a monoclonal antibody capable of inhibiting the activity of vascular endothelial growth factor (VEGF). [47]

Sorafenib, a multikinase inhibitor, was used in the management of a 76-year-old man with a giant cavernous hemangioma measuring more than 20 cm in diameter. Tumor volume decreased from 1492 mL at baseline to 665 mL after 78 days of treatment with sorafenib 600 mg/day. [48]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!